REVA Closes Financing SAN DIEGO, Nov. 20, 2014 (GLOBE

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
REVA Closes Financing

SAN DIEGO, Nov. 20, 2014 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) ("REVA" or the "Company") is pleased to announce that the financing transaction approved by the Company's shareholders at the Special Meeting of Stockholders held in Sydney, Australia on October 31, 2014, has been successfully completed.

Under the terms of the Prospectus dated October 24, 2014 and in accordance with the Convertible Note Deed dated September 25, 2014, REVA issued an aggregate principal amount of US$25 million in senior unsecured convertible notes and 8,750,000 options; each option allows the noteholders to purchase one share of REVA's common stock.

The proceeds from the financing will be used to fund the Company's ongoing operating, clinical and capital needs, including the clinical program for its Fantom™ bioresorbable scaffold. "We are very pleased to announce the close of this financing," said REVA's Chairman and Chief Executive Offer, Bob Stockman. "The funding we have secured will allow REVA to move forward with our clinical plans and to take the product through to CE mark application, which we expect will occur in 2016."

Fantom is a bioresorbable coronary stent made from REVA's proprietary polymer that is designed to dissolve over time, leaving the artery free of a permanent implant and thereby allowing the artery to return to its natural movement or "vasomotion." Due to this temporary nature, bioresorbable stents are commonly referred to as scaffolds. Fantom's polymer properties also enable complete x-ray visibility of the scaffold when placed in the artery, an attribute unique to REVA among bioresorbable scaffolds. REVA believes that this distinct feature will offer a procedural advantage, as x-ray visibility helps confirm proper placement of the scaffold and is a tool interventional cardiologists routinely rely on when implanting metal stents.

About REVA

REVA is a development stage medical device company located in San Diego, California, USA, that is focused on the development, testing, and eventual commercialization of its proprietary bioresorbable stents, which are called "scaffolds" because of their temporary nature. The Company's scaffolds are being developed as an alternative to metal stents, which are small tube-like devices permanently implanted into an artery to treat coronary artery disease. Scaffolds provide restoration of blood flow, support the artery through the healing process, then disappear (or "resorb") from the body over a period of time. This resorption allows the return of natural movement and function of the artery, a result not attainable with permanent metal stents. The Company has conducted clinical studies of its scaffold technologies; a total of 112 patients were enrolled in its most recent clinical trial in Australia, Brazil, Europe, and New Zealand, with enrollment completed during January 2014. The patients in this trial will be followed for a total of five years, with primary data to be obtained at nine and 12 months. The Company is now developing and testing its FantomTM scaffold, with initial human implants planned for late 2014 at multiple centers in Brazil and Europe. The Fantom scaffold has been designed to offer distinct ease-of-use features including complete scaffold visibility under x-ray, expansion with one continuous inflation, no procedural time limitations, and standard storage and handling. REVA will require successful clinical results and regulatory approval before it can commercialize Fantom or any of its other products.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management. All statements that are not statements of historical fact, including those statements that address future operating performance and events or developments that we expect or anticipate will occur in the future, are forward-looking statements, such as those statements regarding our ability to raise financing to fund our operations on terms favorable to us or at all, our ability to obtain the regulatory approvals, our ability to timely and successfully complete our clinical trials, our ability to protect our intellectual property position, our ability to commercialize our products if and when approved, our ability to develop and commercialize new products, and our estimates regarding our capital requirements and financial performance, including profitability. You should not place undue reliance on these forward-looking statements. Although management believes these forward-looking statements are reasonable as and when made, forward-looking statements are subject to a number of risks and uncertainties that may cause our actual results to vary materially from those expressed in the forward-looking statements, including the risks and uncertainties that are described in the "Risk Factors" section of our Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (the "SEC") on March 17, 2014, and as updated in our periodic reports since then. Any forward-looking statements in this announcement speak only as of the date when made. REVA does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

United States Investor & Media Enquiries: REVA Medical, Inc. Cheryl Liberatore Director, Investor Relations +1 858-966-3045 Australia Investor Enquiries: Inteq Limited Kim Jacobs +61 2 9229 2700 Australia Media Enquiries: Buchan Consulting Rebecca Wilson +61 3 9866 4722 Annabel Murphy +61 2 9237 2800

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Berlin Heals Puts Microcurrent Therapy to a Real Test

Updated Category News Views 56

A silent electrical signal is heading into the sort of trial that separates intriguing ideas from credible medical evidence. Berlin Heals Holding AG has initiated C-MIC IV, an international randomized, double-blind, sham-controlled study of its implanted microcurrent therapy for symptomatic heart failure. The first patient has already been implanted in Kragujevac, Serbia....

Continue Reading
Ideas Abu Dhabi Puts Water Innovation on Stage

Updated Category News Views 158

Water rarely gets the spotlight until a pipe fails, a harvest shrinks, or a city starts rationing. That is why the agenda around Ideas Abu Dhabi at the 2026 UN Water Conference deserves more than the usual polite nod given to conference programming. From 7 to 10 December in Abu Dhabi, this is shaping up as a public-facing attempt to connect a hard physical problem with...

Continue Reading
Albany Masonry Waterproofing Is a Quiet Value Play

Updated Category News Views 114

Winter works its mischief one soaked brick at a time. That is the unglamorous truth behind Sean Mulligan's discussion of masonry waterproofing for Albany-area homes. Brick and stone look tough enough to outlast the furniture, the siding, maybe the whole neighborhood. Yet they are porous materials, and in a region where rain, snowmelt, and sharp temperature swings keep...

Continue Reading
Fidelis Puts $140,000 Behind Statewide Postpartum Care

Updated Category News Views 114

A missed postpartum appointment can look like a small administrative failure until it is not. Fidelis Care’s $140,000 round of Here for Your Health maternal health grants is aimed squarely at that unglamorous but consequential gap: keeping new mothers connected to care after delivery, particularly in underserved New York communities. Small Dollars, Very Specific...

Continue Reading
Teachers in Space Takes Its Classroom Model Orbital

Updated Category News Views 82

Two teachers strapped into a research flight may sound like a glossy space-age photo op, but the useful part of this plan sits back in the classroom with the students staring at the data. Teachers in Space wants to send two educators aboard a Virgin Galactic research flight expected in 2027, and it is raising $2 million to fund the broader educational program and mission....

Continue Reading
Physiatry or Orthopedics: Sorting Out Pain Care Choices

Updated Category News Views 47

Pain care gets muddled the minute people assume every ache needs the same doorway. Dr. Mala Young, a physical medicine and rehabilitation expert in Ann Arbor, Michigan, makes a useful distinction: a physiatrist and an orthopedic doctor may both see pain, mobility trouble, and injury, but they are not interchangeable. That sounds obvious until someone is staring at back...

Continue Reading
Gozney Brings in Armin Boehm for a Global Growth Push

Updated Category News Views 117

A pizza oven company has just made a very grown-up management move. Gozney appointed Armin Boehm as Global President, effective from October 31, putting an experienced consumer-brand operator beside founder, designer and CEO Tom Gozney at a moment when the business says it is becoming a global omnichannel operation. This is not the sort of announcement that comes with...

Continue Reading
TGHL Eyes U.S. Battery Shift Through EnChem Merger

Updated Category News Views 220

A Policy Squeeze Is Rewriting the Battery Map Battery supply chains are getting shoved through a narrower gate, and that is exactly why this proposed deal deserves a hard look. The GrowHub Limited wants to acquire EnChem America, a Georgia-based lithium-ion battery electrolyte producer, and the timing is plainly built around Washington's push to reduce reliance on...

Continue Reading
Receipts Turns Vegas Party Shirts Into AR Keepsakes

Updated Category News Views 22

A shirt that coughs up a Vegas weekend when scanned is either a smart little keepsake trick or a privacy headache wearing sequins. Receipts™, introduced by Las Vegas-based Naked City Couture and the AR Trading Card Company, is betting it can be the former. The concept is simple enough: friends wear the apparel, capture photos and videos during a trip, upload those...

Continue Reading
Vertex Extends Genomics Pact With $220M in Potential

Updated Category News Views 177

Eight years is long enough to separate a useful science partner from a glossy slide deck, and Vertex’s decision to add four more years with Genomics deserves attention. This is not a splashy acquisition, nor is it a clean revenue number investors can plug into next quarter’s model. It is a deeper commitment to the slow, expensive, wonderfully unforgiving business of...

Continue Reading

Top 5 Most Recently Viewed Articles

Impact of Withdrawal on Menthol Cigarette Regulation Efforts

Updated Category News Views 158

The Trump Administration's Recent Decision Recently, the Trump administration made headlines by withdrawing a previously proposed ban on menthol cigarettes in the United States. This decision marks a significant setback for health regulators and activists who have long been advocating for healthier tobacco policies. Background of the Proposal In April 2022, the Food and...

Continue Reading
Carta Healthcare Secures Gold by Innovating Clinical Data

Updated Category News Views 18

Tackling a Stubborn Healthcare Pain Point Let's face it: the healthcare industry's data management game has been sweating buckets over a Herculean task for years. A staggering $10-15 billion gets burned annually thanks to inefficient clinical data abstraction. Today's hero of this tale? Carta Healthcare, which just snagged a shining Gold at the 2026 Stevie Awards in...

Continue Reading
SentinelOne Earns Prestigious Recognition from Gartner for 2024

Updated Category News Views 456

SentinelOne's Recent Achievement in Cloud Security SentinelOne (NYSE: S), a prominent player in the field of AI-driven security solutions, has recently been acknowledged as a Customers' Choice in the 2024 Gartner® Peer Insights™ report specifically for Cloud-Native Application Protection Platforms. This recognition reflects feedback from a broad user base, emphasizing...

Continue Reading
Tingus Goose: A Premium Idle Game Experience on Steam

Updated Category News Views 201

Exciting Announcement for Gamers The cult phenomenon, Tingus Goose, is making its debut on Steam as a fully enhanced 1.0 edition designed for PC players. Co-published by Playsaurus and Ultraplayers, this adaptation aims to deliver the ultimate idle gaming experience, free from the distractions found in mobile versions. What’s New in Tingus Goose? Unique Gameplay...

Continue Reading
TrackerRMS Launches Innovative Onboarding+ Solution for Staffing

Updated Category News Views 368

Introducing the New Onboarding+ Solution by TrackerRMS TrackerRMS has taken a significant step in revolutionizing the recruitment landscape with the introduction of its Onboarding+ solution. This innovative tool is designed specifically for recruitment agencies looking to enhance their onboarding process and improve the overall candidate journey. By integrating advanced...

Continue Reading